Dyne Therapeutics, Inc. Assets, Fair Value Disclosure
Dyne Therapeutics, Inc. (DYN) had Assets, Fair Value Disclosure of $361.93 million as of 2021-03-31, per its 10-Q filed 2021-05-06.
Discontinued › Notes
us-gaap:AssetsFairValueDisclosure · last filed 2021-05-06
- 2021-03-31: Assets, Fair Value Disclosure $361.93M.
| Period end | Assets, Fair Value Disclosure |
|---|---|
| 2021-03-31 | $361.93M 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |